I am pleased that the collaboration with Cytos is definitely producing a meaningful contribution to Singapore's pandemic readiness, a critical facet of our national protection. The success of this potential vaccine will become of significant impact not only to the region but also the globe. Christian Itin , PhD, Chairman and CEO of Cytos, commented, We are very pleased with the fruitful collaboration which includes led to the clinical begin of this novel influenza vaccine. This is a significant milestone for this program and the initial clinical system using Cytos' B-cell vaccine system for a prophylactic vaccine against an infectious disease.We are continuing to explore multiple combination therapies that enable physicians to choose the best treatment regimens based on patient want.S. Food and Drug Administration seeking acceptance to advertise Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr. UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG filed match against Actavis' on August 21 subsidiaries, 2014 in the U.S.